26 related articles for article (PubMed ID: 34486544)
1. Developmental adaptation of central nervous system to extremely high acetylcholine levels.
Farar V; Hrabovska A; Krejci E; Myslivecek J
PLoS One; 2013; 8(7):e68265. PubMed ID: 23861875
[TBL] [Abstract][Full Text] [Related]
2. [Neuroblastoma-like schwannoma of the lung: report of a case].
Hua HJ; Li KD; Zhu Y; Fan QH; Li H
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):492-494. PubMed ID: 38678334
[TBL] [Abstract][Full Text] [Related]
3. Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development.
Gu Y; Chow MJ; Kapoor A; Mei W; Jiang Y; Yan J; De Melo J; Seliman M; Yang H; Cutz JC; Bonert M; Major P; Tang D
Transl Oncol; 2018 Aug; 11(4):1012-1022. PubMed ID: 29966864
[TBL] [Abstract][Full Text] [Related]
4. A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.
Di Giulio S; Colicchia V; Pastorino F; Pedretti F; Fabretti F; Nicolis di Robilant V; Ramponi V; Scafetta G; Moretti M; Licursi V; Belardinilli F; Peruzzi G; Infante P; Goffredo BM; Coppa A; Canettieri G; Bartolazzi A; Ponzoni M; Giannini G; Petroni M
Oncogene; 2021 Oct; 40(43):6143-6152. PubMed ID: 34508175
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
Arlt B; Zasada C; Baum K; Wuenschel J; Mastrobuoni G; Lodrini M; Astrahantseff K; Winkler A; Schulte JH; Finkler S; Forbes M; Hundsdoerfer P; Guergen D; Hoffmann J; Wolf J; Eggert A; Kempa S; Deubzer HE
Int J Cancer; 2021 Mar; 148(5):1219-1232. PubMed ID: 33284994
[TBL] [Abstract][Full Text] [Related]
6. Butyrylcholinesterase and the control of synaptic responses in acetylcholinesterase knockout mice.
Girard E; Bernard V; Minic J; Chatonnet A; Krejci E; Molgó J
Life Sci; 2007 May; 80(24-25):2380-5. PubMed ID: 17467011
[TBL] [Abstract][Full Text] [Related]
7. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
[TBL] [Abstract][Full Text] [Related]
8. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
9. Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHE Deletion on the Neuroblastoma Growth In Vitro and In Vivo.
Baranowska-Kortylewicz J; Kortylewicz ZP; McIntyre EM; Sharp JG; Coulter DW
J Pediatr Hematol Oncol; 2022 Aug; 44(6):293-304. PubMed ID: 34486544
[TBL] [Abstract][Full Text] [Related]
10. The butyrylcholinesterase knockout mouse a research tool in the study of drug sensitivity, bio-distribution, obesity and Alzheimer's disease.
Duysen EG; Li B; Lockridge O
Expert Opin Drug Metab Toxicol; 2009 May; 5(5):523-8. PubMed ID: 19416087
[TBL] [Abstract][Full Text] [Related]
11. The MYCN oncogene and differentiation in neuroblastoma.
Westermark UK; Wilhelm M; Frenzel A; Henriksson MA
Semin Cancer Biol; 2011 Oct; 21(4):256-66. PubMed ID: 21849159
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
